摘要
目的：探讨舒利迭与噻托溴铵联合应用治疗慢性阻塞性肺疾病的临床疗效。方法：选取2012年6月∽2014年2月于我院呼吸科就诊的182慢性阻塞性肺疾病患，将其随机分为对照组（ n＝100）和治疗组（ n＝82）。实施常规治疗，对照组采用噻托溴铵吸入疗法，治疗组采用舒利迭与噻托溴铵联合应用吸入疗法。密切观察治疗前后肺功能的改变并记录临床症状。结果：治疗组治疗后肺功能FEV1、FCV和FEV1％的预测值均高于对照组，差异有统计学意义（ P＜0．05）；治疗组MMRC、6MWT评分高于对照组，差异有统计学意义（ P＜0．05）。结论：舒利迭与噻托溴铵联合应用疗法，不仅可以提高了患者的肺功能，改善患者的症状和体征，还减少慢性阻塞性肺疾病急性发作的次数，值得在临床上进一步推广应用。
Objective：To investigate the clinical efficacy of seretide and tiotropium bromide in the treatment of chronic obstructive pul -monary disease .Methods：From 2012 June -2014 February ,182 patients with chronic obstructive pulmonary disease at the Department of Respiration in People＆#39;s Hospital of Ling Hai City were randomly divided into control group （n=100） and treatment group （n=82）.The implementation of routine treatment , the control group using tiotropium bromide inhalation therapy , treatment group were treated with seretide and tiotropium bromide combined inhaled therapy .Closely observed pulmonary function before and after treatment and recorded the clinical symptoms change .Results：after treatment, FEV1, FCV prediction of pulmonary function and the value of FEV 1%was higher than that of control group , the difference was statistically significant （P 〈0.05）;group MMRC, 6MWT was higher than that of the con-trol group, the difference was statistically significant （P 〈0.05）.Conclusion：combined therapy with seretide and tiotropium bromide , not only can improve the pulmonary function of patients , improve the patient＆#39;s symptoms and signs , but also reduce the times of acute exac-erbation of chronic obstructive pulmonary disease , worthy of further application in clinical practice .
出处
《中国伤残医学》
2014年第23期24-25,共2页
Chinese Journal of Trauma and Disability Medicine
关键词
舒利迭
噻托溴铵
慢性阻塞性肺疾病
联合用药
药物疗法
Sulidie
Tiotropium bromide
Chronic obstructive pulmonary disease
Combined use of drugs
